These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 5371669)

  • 1. [Antimycobacterial activity of rifomycin: in vitro and in vivo studies].
    Tacquet A; Devulder B; Martin JC; Daniel H; Le Bouffant L
    Acta Tuberc Pneumol Belg; 1969; 60(3):366-89. PubMed ID: 5371669
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experimental research on the antimycobacterial activity of rifampicine: 3-(4-methyl-l-piperazinyl-iminomethyl)-rifomycin SV].
    Lucchesi M; Mancini P; Zubiani M
    Ann Ist Carlo Forlanini; 1967; 27(2):119-36. PubMed ID: 4973676
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experimental studies of the antimycobacterial activity of Rifampicine].
    Nitti V; Catena E; Ninni A; Di Filippo A
    Arch Tisiol Mal Appar Respir; 1966 Nov; 21(11):867-910. PubMed ID: 4969274
    [No Abstract]   [Full Text] [Related]  

  • 4. [In-vitro antimycobacterial activity of rifapentine (comparison with rifampicin)].
    Tsukamura M; Mizuno S; Toyama H
    Kekkaku; 1986 Dec; 61(12):633-9. PubMed ID: 3573500
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antimycobacterial activity of rifomycin in vitro in various media].
    Hennebert A
    Acta Tuberc Pneumol Belg; 1969; 60(3):348-55. PubMed ID: 4984418
    [No Abstract]   [Full Text] [Related]  

  • 6. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
    Pattyn SR; Hébrant F
    Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv.
    Ahmad Z; Sharma S; Khuller GK
    FEMS Microbiol Lett; 2005 Oct; 251(1):19-22. PubMed ID: 16143463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Runyon Group I Mycobacteria to rifampicin.
    Saito H; Yamamoto S; Yamura T
    Hiroshima J Med Sci; 1972 Mar; 21(1):35-40. PubMed ID: 4661749
    [No Abstract]   [Full Text] [Related]  

  • 9. [Quality control of culture media for mycobacterium drug sensitivity tests].
    Kekkaku; 2003 Aug; 78(8):563-8. PubMed ID: 14582504
    [No Abstract]   [Full Text] [Related]  

  • 10. Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.
    Pallanza R; Arioli V; Furesz S; Bolzoni G
    Arzneimittelforschung; 1967 May; 17(5):529-34. PubMed ID: 5631580
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and antimycobacterial activity of some 4-pyridinecarboxyamidrazone derivatives.
    Mamolo MG; Vio L; Banfi E; Predominato M; Fabris C; Asaro F
    Farmaco; 1993 Apr; 48(4):529-38. PubMed ID: 8357468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the structure and antimycobacterial activity of substituted salicylanilides.
    Waisser K; Bures O; Holý P; Kunes J; Oswald R; Jirásková L; Pour M; Klimesová V; Kubicová L; Kaustová J
    Arch Pharm (Weinheim); 2003 Mar; 336(1):53-71. PubMed ID: 12666254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Number of rifampicin- and ethambutol-resistant variants in strains of atypical mycobacteria pathogenic for man, on Loewenstein-Jensen media].
    Le Lirzin M; Boisvert H
    Ann Inst Pasteur (Paris); 1971 Apr; 120(4):549-59. PubMed ID: 5564197
    [No Abstract]   [Full Text] [Related]  

  • 14. Rifampin: in vitro effect on atypical mycobacteria.
    Rynearson TK; Shronts JS; Wolinsky E
    Am Rev Respir Dis; 1971 Aug; 104(2):272-4. PubMed ID: 5558997
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium.
    Dutta NK; Kumar KA; Mazumdar K; Dastidar SG
    Indian J Exp Biol; 2004 Sep; 42(9):922-7. PubMed ID: 15462188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
    Heginbothom ML
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria.
    Sohn H; Lee KS; Ko YK; Ryu JW; Woo JC; Koo DW; Shin SJ; Ahn SJ; Shin AR; Song CH; Jo EK; Park JK; Kim HJ
    Int J Antimicrob Agents; 2008 Jun; 31(6):567-71. PubMed ID: 18337064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
    Prado S; Janin YL; Saint-Joanis B; Brodin P; Michel S; Koch M; Cole ST; Tillequin F; Bost PE
    Bioorg Med Chem; 2007 Mar; 15(5):2177-86. PubMed ID: 17208445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives.
    Ortega MA; Montoya ME; Jaso A; Zarranz B; Tirapu I; Aldana I; Monge A
    Pharmazie; 2001 Mar; 56(3):205-7. PubMed ID: 11265583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo antimycobacterial activity of an antihypertensive agent methyl-L-DOPA.
    Dutta NK; Mazumdar K; Dastidar SG; Chakrabarty AN; Shirataki Y; Motohashi N
    In Vivo; 2005; 19(3):539-45. PubMed ID: 15875773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.